Osimertinib decreases Topo IIα levels via promoting GSK3-dependent and FBXW7-mediated proteasomal degradation and suppressing SMURF2 expression in EGFRm NSCLC cell lines. Here, SMURF2 is linked to non-small cell lung carcinoma.